ConductScience.org, home

Paper37035239

CDK4/6 inhibitor resistance in estrogen receptor positive breast cancer, a 2023 perspective.

Zhou FH and 5 others. Front Cell Dev Biol, 2023. Cited by 47 papers, by iCite.

Cite this record

ConductScience Library. CDK4/6 inhibitor resistance in estrogen receptor positive breast cancer, a 2023 perspective. Papers, record 37035239. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/37035239

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
CDK4/6 inhibitor resistance in estrogen receptor positive breast cancer, a 2023 perspective.
PubMed
Journal
Front Cell Dev Biol
PubMed
Year
2023
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
47
iCite
Relative citation ratio, by iCite
4.1
iCite
Revised in PubMed
2026-09-19
PubMed

Authors6

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Zhou FHFiona H
2Downton TTeesha
3Freelander AAllegra
4Hurwitz JJoshua
5Caldon CEC Elizabeth
6Lim EElgene

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References103

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
136153348Co-targeting CDK2 and CDK4/6 overcomes resistance to aromatase and CDK4/6 inhibitors in ER+ breast cancer.NPJ Precis Oncol2022https://conductscience.org/library/papers/36153348PubMed
229101163CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation.Cancer Discov2018https://conductscience.org/library/papers/29101163PubMed
334324367Endocrine Treatment and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Update.J Clin Oncol2021https://conductscience.org/library/papers/34324367PubMed
429731395CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought.Cancer Cell2018https://conductscience.org/library/papers/29731395PubMed
529236940Polyclonal RB1 mutations and acquired resistance to CDK 4/6 inhibitors in patients with metastatic breast cancer.Ann Oncol2018https://conductscience.org/library/papers/29236940PubMed
634737452Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial.Nat Med2021https://conductscience.org/library/papers/34737452PubMed
734544752INK4 Tumor Suppressor Proteins Mediate Resistance to CDK4/6 Kinase Inhibitors.Cancer Discov2022https://conductscience.org/library/papers/34544752PubMed
831563959The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial.JAMA Oncol2020https://conductscience.org/library/papers/31563959PubMed
931091374Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer.N Engl J Med2019https://conductscience.org/library/papers/31091374PubMed
1030537512Loss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4/6 Inhibitors via the Hippo Pathway.Cancer Cell2018https://conductscience.org/library/papers/30537512PubMed
1135058503RBL2/DREAM-mediated repression of the Aurora kinase A/B pathway determines therapy responsiveness and outcome in p53 WT NSCLC.Sci Rep2022https://conductscience.org/library/papers/35058503PubMed
1235789445Trophoblast Cell Surface Antigen 2 gene (TACSTD2) expression in primary breast cancer.Breast Cancer Res Treat2022https://conductscience.org/library/papers/35789445PubMed
1327748766Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence.Oncogene2017https://conductscience.org/library/papers/27748766PubMed
1433460574Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study.Lancet Oncol2021https://conductscience.org/library/papers/33460574PubMed
1521367843Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer.Endocr Relat Cancer2011https://conductscience.org/library/papers/21367843PubMed
1631527167Biomarker Analyses of Response to Cyclin-Dependent Kinase 4/6 Inhibition and Endocrine Therapy in Women with Treatment-Naïve Metastatic Breast Cancer.Clin Cancer Res2020https://conductscience.org/library/papers/31527167PubMed
1729716919Abemaciclib, a Selective CDK4/6 Inhibitor, Enhances the Radiosensitivity of Non-Small Cell Lung Cancer In Vitro and In Vivo.Clin Cancer Res2018https://conductscience.org/library/papers/29716919PubMed
1830833638Cyclin D-CDK4 relieves cooperative repression of proliferation and cell cycle gene expression by DREAM and RB.Oncogene2019https://conductscience.org/library/papers/30833638PubMed
1936071033High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer.Nat Commun2022https://conductscience.org/library/papers/36071033PubMed
2035263519Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer.N Engl J Med2022https://conductscience.org/library/papers/35263519PubMed

See all 103 referencesDownload CSV of references

Cited by38

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 47 citations.

PMIDTitleJournalYearIn PapersSource
42964697Endocrine resistance in HR+/HER2- breast cancer: molecular mechanisms and emerging therapeutic strategies.Front Oncol2026https://conductscience.org/library/papers/42964697PubMed
42738414On-Treatment NLR Dynamics During CDK4/6 Inhibition Are Associated with Overall Survival in Metastatic Breast Cancer.Cancers (Basel)2026https://conductscience.org/library/papers/42738414PubMed
42658196Systematic analysis of network-driven adaptive resistance to CDK4/6 and oestrogen receptor inhibition using meta-dynamic network modelling.Elife2026https://conductscience.org/library/papers/42658196PubMed
42289616Abemaciclib in HR+, HER2- Breast Cancer: A Narrative Review of the Clinical Evidence.Oncol Ther2026https://conductscience.org/library/papers/42289616PubMed
42121857Pre-Adaptive States and Evolutionary Trajectories in Breast Cancer Drug Resistance: From Drug-Tolerant Persisters to Clonal Evolution.Cells2026https://conductscience.org/library/papers/42121857PubMed
42088350Dormancy exit correlates with CREB1 reactivation that is a potential target to overcome endocrine therapy resistance in ER+ breast cancer cells.iScience2026https://conductscience.org/library/papers/42088350PubMed
41893011Next Frontier in HER2+/HR+ Breast Cancer: Leveraging Cell Cycle Control with CDK4/6 Inhibitors.J Pers Med2026https://conductscience.org/library/papers/41893011PubMed
41858526Emerging Targeted and Multimodal Therapeutic Strategies in Breast Cancer: A Comprehensive Review.Breast Cancer (Dove Med Press)2026https://conductscience.org/library/papers/41858526PubMed
41714320mTOR-driven autophagy suppression defines metabolic vulnerability in CDK4/6 inhibitor-resistant HR+/HER2- breast cancer.Cell Death Dis2026https://conductscience.org/library/papers/41714320PubMed
41677624Identification of Resistance Genes in Breast Cancer Cells Treated with Fulvestrant and Ribociclib via Retroviral Screening and Integration Site Sequencing.Cells2026https://conductscience.org/library/papers/41677624PubMed
41646442Rectal metastasis in a patient with long-term breast cancer: a rare case report with literature review.Front Oncol2026https://conductscience.org/library/papers/41646442PubMed
41594633Non-Canonical Senescence Phenotype in Resistance to CDK4/6 Inhibitors in ER-Positive Breast Cancer.Biomolecules2026https://conductscience.org/library/papers/41594633PubMed
41351070Concurrent genomic assessment of circulating tumour cells and ctDNA to guide therapy in metastatic breast cancer.BMC Cancer2025https://conductscience.org/library/papers/41351070PubMed
41236673Decoding breast cancer: insights into molecular pathways & therapeutic approaches.Discov Oncol2025https://conductscience.org/library/papers/41236673PubMed
41144934Identification of actionable targets using DEPArray-based sorting of pure carcinoma and stromal populations from formalin-fixed paraffin-embedded tissues followed by shallow whole-genome sequencing.J Pathol2026https://conductscience.org/library/papers/41144934PubMed
40949156Emerging opportunities to treat drug-resistant breast cancer: Discovery of novel small-molecule inhibitors against different targets.Front Pharmacol2025https://conductscience.org/library/papers/40949156PubMed
40947659Effect of Neoadjuvant Hormonal Therapy on Breast Conservation in Invasive Ductal Versus Lobular Carcinoma of the Breast: A Comparative Analysis.J Surg Oncol2025https://conductscience.org/library/papers/40947659PubMed
40830892Phase 1/2 study of H3B-6545 in women with locally advanced/metastatic estrogen receptor-positive, HER2-negative breast cancer.Breast Cancer Res2025https://conductscience.org/library/papers/40830892PubMed
40740245Impact of PIK3CA Mutations on the Clinical Benefits of CDK 4/6 Inhibitors in HR+/HER2- Advanced Breast Cancer: An Updated Pairwise and Network Meta-Analysis.J Cancer2025https://conductscience.org/library/papers/40740245PubMed
40736275PCAIs stimulate MAPK, PI3K/AKT pathways and ROS-Mediated apoptosis in aromatase inhibitor-resistant breast cancer cells while disrupting actin filaments and focal adhesion.Oncotarget2025https://conductscience.org/library/papers/40736275PubMed

See all 38 cited byDownload CSV of cited by

Genes46

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
AKT1207PubTator's text mininghttps://conductscience.org/library/genes/207NCBI Gene
AKT2208PubTator's text mininghttps://conductscience.org/library/genes/208NCBI Gene
AKT310000PubTator's text mininghttps://conductscience.org/library/genes/10000NCBI Gene
AURKA6790PubTator's text mininghttps://conductscience.org/library/genes/6790NCBI Gene
CCND1595PubTator's text mininghttps://conductscience.org/library/genes/595NCBI Gene
CCNE1898PubTator's text mininghttps://conductscience.org/library/genes/898NCBI Gene
CD27429126PubTator's text mininghttps://conductscience.org/library/genes/29126NCBI Gene
CDK21017PubTator's text mininghttps://conductscience.org/library/genes/1017NCBI Gene
CDK41019PubTator's text mininghttps://conductscience.org/library/genes/1019NCBI Gene
CDK61021PubTator's text mininghttps://conductscience.org/library/genes/1021NCBI Gene
CDK91025PubTator's text mininghttps://conductscience.org/library/genes/1025NCBI Gene
CDKN2A1029PubTator's text mininghttps://conductscience.org/library/genes/1029NCBI Gene
CDKN2C1031PubTator's text mininghttps://conductscience.org/library/genes/1031NCBI Gene
DCTN610671PubTator's text mininghttps://conductscience.org/library/genes/10671NCBI Gene
EGFR1956PubTator's text mininghttps://conductscience.org/library/genes/1956NCBI Gene
EP3002033PubTator's text mininghttps://conductscience.org/library/genes/2033NCBI Gene
ERBB22064PubTator's text mininghttps://conductscience.org/library/genes/2064NCBI Gene
EREG2069PubTator's text mininghttps://conductscience.org/library/genes/2069NCBI Gene
ESR12099PubTator's text mininghttps://conductscience.org/library/genes/2099NCBI Gene
FAT12195PubTator's text mininghttps://conductscience.org/library/genes/2195NCBI Gene

See all 46 genesDownload CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/37035239

GET https://conductscience.org/api/papers/v1/37035239/references?page=2